This page was reviewed under our medical and editorial policy by
Frederick L. Durden, Jr, MD, Plastic and Reconstructive Surgeon & Microsurgical Reconstructive Surgeon
This page was updated on February 24, 2023.
Melanoma is a rare but dangerous form of skin cancer that develops in melanocytes, the pigment-producing cells that give skin its color. Desmoplastic melanoma (DM) is an extremely rare form of the disease.
Desmoplastic melanoma is a type of spindle cell melanoma that's more common in male patients than females.
A disease that’s often difficult to identify, desmoplastic melanoma usually lacks pigmentation, commonly resembling benign growths or less dangerous skin cancers (such as basal or squamous cell carcinomas).
According to the American Cancer Society, about 1 percent of all skin cancers are melanomas, and of these melanomas, reviewers in the Journal of the American Academy of Dermatology note that less than 4 percent are desmoplastic melanomas, or tumors characterized by cancerous cells and fibrous tissue with large amounts of collagen.
The pure subtype is less aggressive than the mixed subtype and not as likely to spread to the lymph nodes.
The main cause of this type of melanoma, as with other skin cancer types, is exposure to natural or artificial ultraviolet (UV) rays.
Desmoplastic melanomas most often develop on the head and neck or other areas that have received heavy sun exposure over a person’s lifetime. Because DM is so uncommon, it hasn’t been heavily studied. However, genetic mutations caused by exposure to UV rays are the main cause of desmoplastic melanoma.
In addition to UV light exposure, the following factors also are associated with an increased risk for developing desmoplastic melanoma:
Desmoplastic melanoma (DM) may initially look like a scar, with patches of skin that appear thickened and are either pink or the same tone as the rest of the patient's skin.
Though DM is most often located on the head or neck, it may also be found on:
Desmoplastic melanomas may be difficult to differentiate from noncancerous growths because they’re often amelanotic, meaning they lack pigmentation.
Possible symptoms include:
Desmoplastic melanomas are tricky to identify because they don’t neatly follow the ABCDEs, or typical characteristics of melanomas:
Because early detection is difficult, and because the disease is so rare, desmoplastic melanoma is most often diagnosed in its more advanced stages.
To diagnose desmoplastic melanoma, the doctor gathers the patient’s full medical history, both personal and familial. Touching the area is an important part of diagnosis, too, because a distinct feature of most DM lesions is hardening of the area.
A dermoscopy may be done, in which the skin is examined with a device called a dermoscope (handheld visual aid). In addition, the patient may undergo a biopsy of the entire lesion (called an excision).
A pathology report with the biopsy results typically is sent to the doctor. The pathology report may include:
Additional imaging and blood tests may be performed as well.
First-line treatment of desmoplastic melanoma consists of surgical excision, completely removing the lesion along with a margin of tissue around it. The amount of healthy tissue removed is individualized and based on the depth and thickness of the patient’s melanoma.
For lesions that are more advanced (usually greater than 4 mm), radiation therapy may also be recommended.
Checkpoint inhibitors (immunotherapy drugs that boost the immune system to fight against cancer cells) may also be used to treat desmoplastic melanomas, but research is ongoing, according to the National Cancer Institute. Clinical trials for the checkpoint inhibitor Keytruda® (pembrolizumab) have offered promising results.
When compared with the survival rates of all melanomas, desmoplastic melanoma survival rates tend to be slightly higher.
The five-year relative survival rate represents the percentage of people still alive five years after a cancer diagnosis compared with people who don’t have that type of cancer. According to a 2017 study in ePlasty, the five-year survival rate for desmoplastic melanoma is 75 percent, and five-year disease-free survival is 62 percent.
While the survival rates of desmoplastic melanoma are promising overall, there’s still a lot about this type of melanoma—and others—that researchers don’t know yet.